HTGC - Hercules Capital, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
10.39
+0.07 (+0.71%)
As of 11:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.32
Open10.54
Bid10.34 x 800
Ask10.36 x 900
Day's Range10.34 - 10.58
52 Week Range5.42 - 16.40
Volume151,460
Avg. Volume1,145,755
Market Cap1.15B
Beta (5Y Monthly)1.51
PE Ratio (TTM)13.19
EPS (TTM)0.79
Earnings DateJul. 30, 2020 - Aug. 03, 2020
Forward Dividend & Yield1.28 (12.40%)
Ex-Dividend DateMay 13, 2020
1y Target Est11.81
  • Hercules Capital Gets SBA Green Light Letter for SBIC License
    Zacks

    Hercules Capital Gets SBA Green Light Letter for SBIC License

    Hercules Capital (HTGC) receives a "green light" letter from the SBA to obtain the license to form its third SBIC subsidiary.

  • GlobeNewswire

    Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced it has agreed to terms with Hercules Capital, Inc. (HTGC) on a debt facility to provide up to $80 million of new capital, and will receive $15M under a restructured royalty monetization agreement with HealthCare Royalty Partners (HCR) for elobixibat in the treatment of chronic constipation in Japan. Elobixibat, approved in Japan for the treatment of patients with chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. “These funding arrangements with new and existing partners provide the company additional flexibility and cash runway into the beginning of 2022, past the planned approval and commercial launch of odevixibat for the treatment of progressive familial intrahepatic cholestasis,” said Ron Cooper, President and Chief Executive Officer of Albireo.

  • Hercules Capital Receives SBA "Green Light" Letter Approval to Complete Its Third SBIC License
    Business Wire

    Hercules Capital Receives SBA "Green Light" Letter Approval to Complete Its Third SBIC License

    Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that the U.S. Small Business Administration ("SBA") has issued a "green light" or "go forth" letter inviting Hercules to finalize its application process to obtain a license to form and operate a third Small Business Investment Company ("SBIC") subsidiary, following the Company’s recent presentation to the SBA committee.

  • Hercules Capital Completes 5-Year Investment Grade Bond Offering of $70.0 Million of 4.31% Notes due June 2025
    Business Wire

    Hercules Capital Completes 5-Year Investment Grade Bond Offering of $70.0 Million of 4.31% Notes due June 2025

    Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company") today announced the completed issuance of a private offering in aggregate principal amount of $70.0 million 4.31% Notes due June 2025 (the "June Notes"). On February 5, 2020, the Company completed the initial issuance of $50.0 million 4.28% Notes due February 2025, which were initially assigned a BBB+ rating by Kroll Bond Rating Agency.

  • Hercules Tech (HTGC) Up 4.5% Since Last Earnings Report: Can It Continue?
    Zacks

    Hercules Tech (HTGC) Up 4.5% Since Last Earnings Report: Can It Continue?

    Hercules Tech (HTGC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital

    G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $100 million. G1 plans to use the proceeds to fund commercialization and further development of trilaciclib, its first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

  • Thomson Reuters StreetEvents

    Edited Transcript of HTGC earnings conference call or presentation 4-May-20 9:00pm GMT

    Q1 2020 Hercules Capital Inc Earnings Call

  • Hercules Capital (HTGC) Q1 Earnings Beat on Higher Revenues
    Zacks

    Hercules Capital (HTGC) Q1 Earnings Beat on Higher Revenues

    A rise in total investment income supports Hercules Capital's (HTGC) Q1 earnings.

  • Hercules Technology Growth Capital (HTGC) Q1 2020 Earnings Call Transcript
    Motley Fool

    Hercules Technology Growth Capital (HTGC) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Hercules Capital Q1 2020 earnings conference call. With us on the call today from Hercules are Scott Bluestein, CEO and chief investment officer; and Seth Meyer, CFO. Hercules first-quarter 2020 financial results were released just after today's market close and can be accessed from Hercules Investor Relations section at htgc.com.

  • Hercules Technology (HTGC) Q1 Earnings and Revenues Top Estimates
    Zacks

    Hercules Technology (HTGC) Q1 Earnings and Revenues Top Estimates

    Hercules Tech (HTGC) delivered earnings and revenue surprises of 2.78% and 5.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Hercules Capital Reports First Quarter 2020 Financial Results
    Business Wire

    Hercules Capital Reports First Quarter 2020 Financial Results

    Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the first quarter ended March 31, 2020.

  • Hercules Capital Declares Cash Distribution of $0.32 per Share for the First Quarter of 2020
    Business Wire

    Hercules Capital Declares Cash Distribution of $0.32 per Share for the First Quarter of 2020

    Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a first quarter 2020 cash distribution of $0.32 per share. The following shows the key dates of the first quarter 2020 distribution payment:

  • Hercules Capital Announces Date of 2020 Annual Meeting of Stockholders and Special Meeting of Stockholders
    Business Wire

    Hercules Capital Announces Date of 2020 Annual Meeting of Stockholders and Special Meeting of Stockholders

    Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), will conduct both its 2020 Annual Meeting of Stockholders and its Special Meeting of Stockholders by virtual meeting on Friday, June 12, 2020 at 9:00 a.m. and 10:00 a.m. (Pacific Time), respectively. The proxy statement for each meeting will be mailed separately on or about April 29, 2020 to shareholders of record as of April 20, 2020.

  • Hercules Capital Announces Date for Release of First Quarter 2020 Financial Results and Conference Call
    Business Wire

    Hercules Capital Announces Date for Release of First Quarter 2020 Financial Results and Conference Call

    Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its first quarter 2020 financial results conference call for Monday, May 4, 2020, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day.

  • Hercules Capital Business and Coronavirus Update
    Business Wire

    Hercules Capital Business and Coronavirus Update

    The team at Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company") is working collectively with our employees, shareholders, stakeholders, bondholders, rating agencies, portfolio companies, and our venture capital and private equity sponsors to navigate the significant challenges created by the unprecedented COVID-19 (Coronavirus) pandemic. We are vigilantly monitoring this evolving situation and have implemented actions to keep our employees safe while also managing the continuity of our business. Our thoughts and prayers are with everyone who has been impacted by these events.

  • Thomson Reuters StreetEvents

    Edited Transcript of HTGC earnings conference call or presentation 20-Feb-20 10:00pm GMT

    Q4 2019 Hercules Capital Inc Earnings Call

  • Hercules Technology (HTGC) Earnings Expected to Grow: Should You Buy?
    Zacks

    Hercules Technology (HTGC) Earnings Expected to Grow: Should You Buy?

    Hercules Tech (HTGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital

    ChemoCentryx, Inc., (CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc. (HTGC), a leader in customized financing for companies in life sciences and technology-related markets. “Through this non-dilutive credit mechanism, we have options to strengthen our robust balance sheet as we advance avacopan towards commercialization in ANCA vasculitis,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. The $100 million credit facility from Hercules Capital comprises three tranches over the next two years to be drawn at ChemoCentryx’s discretion as follows: the first tranche of $40 million is available through December 2020, $20 million of which would be available upon the submission of the avacopan New Drug Application (NDA) for the treatment of ANCA vasculitis; the second tranche of $30 million is available through December 2021 upon NDA approval of avacopan for the treatment of ANCA vasculitis (NDA Approval); the remaining $30 million is available through December 2022, subject to certain conditions.

  • GlobeNewswire

    Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions

    Low-interest (3-month LIBOR plus 3%) loan facility from Sumitomo Dainippon Pharma increased to allow repayment of pre-existing debtHiroshi Nomura, President, CEO, and.

  • Loan Originations, Solid Liquidity Aid Hercules Capital (HTGC)
    Zacks

    Loan Originations, Solid Liquidity Aid Hercules Capital (HTGC)

    Hercules Capital (HTGC) remains well-positioned for growth based on its strong liquidity position, improving economy and robust loan originations.

  • Top Ranked Income Stocks to Buy for November 29th
    Zacks

    Top Ranked Income Stocks to Buy for November 29th

    Top Ranked Income Stocks to Buy for November 29th

  • Asset Growth Aids BlackRock's Top Line Despite High Costs
    Zacks

    Asset Growth Aids BlackRock's Top Line Despite High Costs

    While solid AUM balance is expected to support BlackRock's (BLK) revenue growth, higher costs will likely hurt the bottom line.